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Abstract
The Metabolic Syndrome (MetS) is a complex, multifactorial disorder that develops slowly
over time presenting itself with large differences among MetS patients. We applied a sys-
tems biology approach to describe and predict the onset and progressive development of
MetS, in a study that combined in vivo and in silico models. A new data-driven, physiological
model (MINGLeD: Model INtegrating Glucose and Lipid Dynamics) was developed, describ-
ing glucose, lipid and cholesterol metabolism. Since classic kinetic models cannot describe
slowly progressing disorders, a simulation method (ADAPT) was used to describe longitudi-
nal dynamics and to predict metabolic concentrations and fluxes. This approach yielded a
novel model that can describe long-term MetS development and progression. This model
was integrated with longitudinal in vivo data that was obtained from male APOE*3-Leiden.
CETP mice fed a high-fat, high-cholesterol diet for three months and that developed MetS
as reflected by classical symptoms including obesity and glucose intolerance. Two distinct
subgroups were identified: those who developed dyslipidemia, and those who did not. The
combination of MINGLeD with ADAPT could correctly predict both phenotypes, without
making any prior assumptions about changes in kinetic rates or metabolic regulation. Model-
ing and flux trajectory analysis revealed that differences in liver fluxes and dietary choles-
terol absorption could explain this occurrence of the two different phenotypes. In individual
mice with dyslipidemia dietary cholesterol absorption and hepatic turnover of metabolites,
including lipid fluxes, were higher compared to those without dyslipidemia. Predicted differ-
ences were also observed in gene expression data, and consistent with the emergence of
insulin resistance and hepatic steatosis, two well-known MetS co-morbidities. Whereas
MINGLeD specifically models the metabolic derangements underlying MetS, the simulation
method ADAPT is generic and can be applied to other diseases where dynamic modeling
and longitudinal data are available.
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Author summary
Obesity is becoming a growing health problem, with the risk of running into a disease
state called the Metabolic Syndrome (MetS). It is difficult to study MetS in humans as it
develops over a long period of time while many processes and organs are involved. More-
over, each patient may present itself with different characteristics. We combined data
from animal experiments with a computer model and computer simulations to study the
development of MetS. The new model correctly predicts which changes in the underlying
metabolic processes could explain the MetS symptoms. Unexpectedly, two different sub-
groups were identified: those with high cholesterol and high triglycerides, and those with-
out. The computer model found that in those who develop lipid abnormalities, both
dietary cholesterol absorption and hepatic liver fluxes were higher.
Introduction
The simultaneous presentation of obesity, dyslipidemia, insulin resistance and hypertension is
generally referred to as the Metabolic Syndrome (MetS) [1–5]. Together, these factors impose
increased risk for the development of co-morbidities including cardiovascular disease, type 2
diabetes and non-alcoholic fatty liver disease [6,7]. MetS is considered to be the result of an
imbalance in the mechanisms controlling dietary intake, energy expenditure, glucose handling
and lipid homeostasis [8–10]. The high prevalence of obesity and MetS [11–15], in combina-
tion with the heterogeneous presentation of MetS patients [16,17], asks for the design of ade-
quate treatment and prevention strategies. Clinical research on MetS is mostly cross-sectional
in nature and tends to focus on either lipid or glucose metabolism, while both make up MetS.
Knowledge on the interplay between these different metabolic components during the rela-
tively slow progression into disease is therefore limited, but which a systems biology approach
could provide.
Modeling efforts in the past have shown that systems biology can be a powerful approach to
gain both qualitative and quantitative insight in the inherently complex systems that drive the
development of MetS. For example, Lu et al. [18] demonstrated how HDL raising modulators
fail to reduce cardiovascular disease by elucidating the effects on the reverse cholesterol trans-
port pathway. Likewise, Topp et al. [19] have identified different response pathways and physi-
ological outcomes during prolonged hyperglycemia.
However, these computational models were designed to model the healthy [18,20–29] or
diseased state exclusively [19,30]. Furthermore, these models only describe short-term dynam-
ics (e.g. the postprandial response period) and do not take into account long-term dynamics
that may be expected to occur in progressive diseases such as MetS. Moreover, models that do
explicitly study the gradual phenotype transition into a diseased state, have only considered
either the lipid component [31] or the glucose component [32–35] of MetS.
In addition, a long-term simulation method has been developed referred to as Analysis of
Dynamic Adaptations in Parameter Trajectories (ADAPT) [36–38]. It infers time-varying
parameters that gradually change over time, reflecting the slow change in regulation of meta-
bolic processes during disease development. Therefore, ADAPT is a very powerful approach to
study longitudinal development of diseases and therapeutic interventions and uses experimen-
tal data to infer adaptations in the system [36,37,39,40]. In previous studies, ADAPT has been
applied to study hepatic steatosis [37,39], and treatment of type 2 diabetes [40], but has not yet
been applied to study the full metabolic complexity of MetS.
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Therefore, we aimed to design a computational, data-driven approach to study the longitu-
dinal and progressive dynamics of the majority of metabolic alterations of MetS, i.e. obesity,
glucose intolerance, insulin resistance and dyslipidemia. We employed a systems biology
methodology that integrates three main concepts to infer metabolic adaptations during MetS
development: i) the long-term simulation method ADAPT, combined with ii) a newly devel-
oped in silico MetS model that describes the metabolic processes involved in whole-body car-
bohydrate and lipid metabolism, and integrated with iii) time-series data obtained from an in
vivo MetS model. The APOE3-Leiden(E3L).CETP mouse [41,42] is a mouse model for
human MetS that develops diet-induced dyslipidemia and is prone to develop obesity and
insulin resistance. It has been used in cross-sectional studies addressing different metabolic
facets of MetS [41,43–51]. We made use of this model to study the development of diet-
induced MetS in a longitudinal setting [48,52] by collecting measurements in the same animals
within a three-month period and at multiple intermediate time points.
Our in silico modeling quantitatively analyzes and integrates the experimental data and pro-
vides estimates of metabolite concentrations and fluxes that were experimentally not mea-
sured. With this modeling approach, we demonstrate when and how the onset and
development of MetS occurs. Although we expected to find a homogeneous population, our
modeling approach shows the emergence of different phenotypes of MetS. This heterogeneity
is associated with differences in intestinal and hepatic metabolic fluxes.
Results
We combined data-driven and physiology-based modeling. Hereto we integrated prior knowl-
edge on the complex metabolic systems that underlie the pathophysiology of MetS with experi-
mental observations on the actual metabolic status over time: in vivo data of the onset and
progressive development of MetS have been collected from 11-week-old male E3L.CETP mice
that were fed diets differing in fat and cholesterol content and were followed for three months.
These diets comprised of a low-fat diet (LFD; 20% of energy from fat; n = 8), high-fat diet
(HFD; 60% of energy from fat; n = 12) and a high-fat diet with additional dietary cholesterol
(HFD+C; 0.25% cholesterol; n = 8). For each diet group, longitudinal data was obtained
throughout the time course of the study: body weight was monitored weekly, plasma markers
were measured monthly and liver lipids were assessed after three months. S1 Note provides a
detailed overview of the experimental set-up and measurement details.
Male E3L.CETP mice on a high-fat diet with cholesterol develop obesity,
glucose intolerance and dyslipidemia
Fig 1 presents the results of feeding LFD, HFD and HFD+C as average (left) and individually
(right) for HFD+C feeding; the latter will be discussed in the next paragraph. All individual
datasets are also available in S1 Data. As compared with LFD feeding, increased fat intake
(HFD) resulted in increased weight gain (Fig 1A) reflected by a marked increase in fat mass
(Fig 1B) with no changes in lean mass (Fig 1C). HFD feeding also significantly increased fast-
ing plasma glucose (Fig 1D) and insulin (Fig 1E) levels. Although HFD did not affect the
plasma total cholesterol level (TC; Fig 1G), a shift in the lipoprotein ratio was observed,
reflected by increased plasma HDL-cholesterol (HDL-C) levels (Fig 1H) upon feeding a high-
fat diet.
As compared to the HFD alone, obesity development was slightly increased by cholesterol
feeding (Fig 1A and 1B), as monitored by increased fat mass at three months after starting the
diet, even though the daily food intake did not increase (data not shown). Although the addi-
tional dietary cholesterol did not affect plasma glucose and insulin levels (Fig 1D and 1E), it
In vivo and in silico dynamics of the development of Metabolic Syndrome
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did impair glucose tolerance in the oral glucose tolerance test (see S1 Note–Fig 1), indicating
that dietary cholesterol increased insulin resistance.
As compared to HFD, plasma triglyceride (TG) levels were significantly increased after
three months of feeding HFD with cholesterol (Fig 1F). Cholesterol feeding did not seem to
have an effect on circulating TC levels until the second month of the dietary induction (Fig
Fig 1. In vivo development of the Metabolic Syndrome results in different phenotypes. Experimentally observed metabolic parameters upon dietary induction in
male E3L.CETP mice over the time course of three months is displayed in two ways: in the left panels the data are expressed as mean ± standard deviation (error bars)
for the low-fat diet (LFD; n = 8; light blue), high-fat diet (HFD; n = 12 (pooled from two groups n = 7 for the full time period, n = 5 until 2 months of dietary induction;
dark blue) and high-fat diet with 0.25% cholesterol (HFD+C; n = 8; green) groups, whereas in the right panels the data of the animals on HFD+C are depicted for each
animal individually. Individuals in this cohort were subdivided into two groups based on the plasma triglyceride (TG) and plasma total cholesterol (TC) levels. The
dyslipidemic Metabolic Syndrome phenotypes are depicted in red (MetSDLP; mice with high plasma TG and simultaneous high plasma TC at t = 3 months) and the non-
dyslipidemic Metabolic Syndrome phenotypes in gray (MetSnon-DLP; mice with low plasma TG and simultaneous low plasma TC at t = 3 months). Differences between
groups were determined using one-way ANOVA test. When significant differences were found, Fisher’s LSD test was used as a post hoc test to determine the differences
between two independent groups:  P<0.05;  P<0.01;  P<0.001 HFD as compared to LFD # P<0.05; ## P<0.01; ### P<0.001 HFD+C as compared to HFD.
https://doi.org/10.1371/journal.pcbi.1006145.g001
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1G). Plasma HDL-C level (Fig 1H), on the other hand, was increased after starting the diet
(HFD and HFD+C) over the first two months.
Male E3L.CETP mice respond bimodally to cholesterol feeding suggesting
the presence of two distinct Metabolic Syndrome phenotypes
Male E3L.CETP mice developed HFD-induced obesity, glucose intolerance and dyslipidemia,
mimicking the classical symptoms seen in human MetS. However, the high variability in both
triglyceride and cholesterol levels complicated the interpretation of the dyslipidemic compo-
nent. Therefore, we also presented the data of mice fed with the HFD+C individually in the
right-hand side panels of Fig 1. When inspecting the levels of plasma TG (Fig 1F) and plasma
TC (Fig 1G) at the three months’ time point, the data reveal clear differences among the indi-
vidual mice: while some develop dyslipidemia upon feeding HFD+C (shown in red), others do
not (shown in grey), suggesting a bimodal distribution. With this insight, we divided the HFD
+C cohort into two subgroups: the mode with high plasma TG and high TC levels after three
months of HFD+C is referred to as the dyslipidemic Metabolic Syndrome phenotypes
(MetSDLP; n = 3) and the other mode as the non-dyslipidemic Metabolic Syndrome pheno-
types (MetSnon-DLP; n = 5). This subdivision shows a consistent pattern in both TG and TC at
the three months’ time point, but is already present earlier in time. In fact, the onset of dyslipi-
demia is already noticeable after two months of the diet, and progresses further towards the
three months’ time period. Note that the subdivision in phenotype development is a result of
the HFD+C diet; no baseline differences are observed (t = 0 months in this data set), and these
observations are limited to the HFD+C group and not present in HFD.
This separation into two phenotypes is clearly present in the lipid trait, but it is also
reflected in markers of carbohydrate metabolism. Although the individual mice cannot be sep-
arated based on the fasting plasma glucose (Fig 1D) data, the fasting plasma insulin (Fig 1E)
indicates that the MetSDLP individuals are significantly more insulin resistant than the MetS-
non-DLP individuals after at the three months’ time point. This trend is even more profound in
the insulin dynamics in response to a glucose challenge test (S1 Note-Fig 1): MetSDLP individu-
als show a markedly higher insulin peak that also lasts longer than the MetSnon-DLP individuals.
This indicates that dyslipidemia and glucose intolerance develop in parallel, but it is unclear
how these are causally related.
MINGLeD describes metabolic snapshots accurately
Next, we developed a novel in silico model that is tailored to describe data from longitudinal
studies and simulates the metabolic system governing carbohydrate, lipid and cholesterol
metabolism, providing predictions for unobserved fluxes and metabolites. The Model
INtegrating Glucose and Lipid Dynamics (MINGLeD) is composed of a system of coupled,
nonlinear ordinary differential equations (ODEs). The steady state of the ODE model repre-
sents a snapshot of the metabolic state and describes the mass balance of the metabolite pools
and flux rates for carbohydrate, lipid and cholesterol species in the plasma, liver, intestinal
lumen and periphery (Fig 2). The model aims to describe the metabolic system from a whole-
body perspective under healthy conditions as well as at different stages during MetS develop-
ment. All simulation code and in silico data files are available on GitHub (via https://github.
com/yvonnerozendaal/MINGLeD).
MINGLeD was integrated with the in vivo data whilst considering four subgroups: the LFD
group, HFD group, MetSnon-DLP phenotypes and MetSDLP phenotypes. For each subgroup,
MINGLeD was fitted to the data of each of the four time snapshots separately. The resulting
sixteen models differ in the values for their estimated parameters. For each model the
In vivo and in silico dynamics of the development of Metabolic Syndrome
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parameter estimation procedure was repeated with 500 different initial parameter sets using
multi-start optimization. Fig 3 displays that MINGLeD accurately fits the metabolic snapshots
over time for each of these groups. This shows that MINGLeD is capable of describing differ-
ent metabolic phenotypes upon varying dietary intake and at different metabolic stages in
time.
MINGLeD with ADAPT describes dyslipidemic and non-dyslipidemic
Metabolic Syndrome progression
Calibration of MINGLeD yielded separate models for each subgroup (LFD, HFD, MetSnon-DLP
and MetSDLP). However, this ignores the fact that the phenotypes represented by those four
Fig 2. Schematic representation of the computational model MINGLeD. MINGLeD describes the metabolic pathways of glucose and lipids to describe the
development of MetS. This multi-compartment framework encompasses pathways in dietary absorption, hepatic, peripheral and intestinal lipid metabolism,
hepatic and plasma lipoprotein metabolism and plasma, hepatic and peripheral carbohydrate metabolism. The metabolite pools in the different tissue
compartments are displayed in the frames; the corresponding metabolic fluxes are represented using the arrows. The dashed arrows represent the dietary inflow
in terms of the different macronutrients derived from the experimental data. AA, amino acid; ACAT, Acyl-coenzyme A:cholesterol acyltransferase; ACoA,
Acetyl CoA; BA, bile acid; C, cholesterol; CE, cholesteryl ester; CEH, cholesterol ester hydrolase; CETP, cholesteryl ester transfer protein; CM, chylomicron;
DNL, de novo lipogenesis; (F)C, (free) cholesterol; (F)FA, (free) fatty acid; G, glucose; G6P, glucose-6-phosphate; GNG, gluconeogenesis; HDL, high density
lipoprotein; TG, triglyceride; TICE, transintestinal cholesterol absorption; (V)LDL, (very) low density lipoprotein.
https://doi.org/10.1371/journal.pcbi.1006145.g002
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models are causally connected in time. MINGLeD describes metabolic fluxes and concentra-
tions but does not explicitly include the multiple pathways that regulate and modulate metabo-
lism over a three-month time period (such as changes in gene expression and protein activity).
Both limitations were overcome by combining MINGLeD with a dedicated approach for lon-
gitudinal modeling of biological systems: ‘Analysis of Dynamic Adaptations of Parameter
Fig 3. MINGLeD describes metabolic phenotypes of male E3L.CETP mice upon different diets and time points. The metabolic phenotypes are depicted for three
different diets (with HFD+C composed of two subgroups that emerged after two months of dietary induction) at four different time points. Model fits (colored error
bars: mean ± standard deviation) of MINGLeD calibrated to the phenotype snapshots (raw, individual mouse data shown in gray) separately. Only acceptable model
simulations were included, which was classified as having a weighted sum of squared errors (see Eq 1 in S3 Note) below 100.
https://doi.org/10.1371/journal.pcbi.1006145.g003
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Trajectories’ (ADAPT) [36–38]. ADAPT uses the experimental data to infer adaptations in
the system, which is implemented by introducing time-varying model parameters. Model
parameters are iteratively re-estimated over the time course of the simulation, yielding
parameter trajectories that govern the time-dependent evolution of the modeled state vari-
ables and fluxes. Combining MINGLeD with ADAPT and the experimental data resulted in
a dynamic, continuous model of MetS development and progression. ADAPT uses ensem-
ble-based simulation to account for both methodological and experimental uncertainty
resulting from biological variability and relatively low power in the HFD+C subgroups. By
repeated Monte Carlo sampling of the in vivo data, sampled datasets are generated and for
each sampled dataset a parameter trajectory was estimated. This was repeated resulting in a
set of 1,000 simulated models yielding a database comprising of in silico populations of
1,000 virtual individuals for each subgroup. Each simulation describes the experimental
data adequately, though with variation in parameter trajectories yielding differences in
fluxes and concentrations, especially for model variables that are not experimentally
observed. A more detailed explanation of the ADAPT methodology is given in the Online
Methods.
Fig 4 shows that the simulated trajectories for the plasma metabolites fit the in vivo data
points accurately and provide a continuous description of the dynamics with which the system
behaves over time, illustrating the different trajectories for the different subgroups. Note that
ADAPT did not yield one single simulation but provided ensembles of state and flux trajecto-
ries. Each line in Fig 4 is one trajectory solution, where a darker color represents more overlap
(higher density) of trajectory solutions in that region. These density plots cover the solution
space for each of the modeled components. To aid visual analysis, the mean of the trajectory
distributions for each of the subgroups is depicted in the panels to the far-right. These trajecto-
ries illustrate the clear distinction that can be made between the dyslipidemic and non-dyslipi-
demic MetS phenotypes.
Flux trajectory analysis identifies distinct differences in dietary cholesterol
absorption and hepatic metabolism during dyslipidemia
We showed that the in silico model accurately captures the trends as observed in the in vivo
data. The ensembles of simulated concentration and flux trajectories provide insight in how
the underlying metabolic network is affected upon emergence of the two different MetS phe-
notypes. Fig 5 displays the median with 10% range of the collection of trajectories for several
metabolic fluxes. Clear differences between the dyslipidemic and non-dyslipidemic MetS phe-
notypes can be observed. A complete overview of all model state trajectories and metabolic
flux trajectories is documented in S1 Fig.
Despite equal intake of food and thus cholesterol, dietary cholesterol absorption from the
intestinal lumen was markedly higher in the dyslipidemic compared to the non-dyslipidemic
MetS group (Fig 5A), which may have promoted the development of dyslipidemia.
The modeling also predicted that within the dyslipidemic phenotype, rates of lipid shuttling
towards (V)LDL-TG uptake (Fig 5B; see also S1K–S1L Fig) were increased, as higher rates of
hepatic fatty acid uptake (Fig 5C) and lipogenesis (Fig 5E) were observed accompanied by a
lower rate of hepatic β-oxidation (Fig 5F).
We observed similar changes if we analyze the gene expression data (S1 Note-Table 3) from
the same animals: we could qualitatively relate our flux predictions with the gene expression
profiles of the fully developed MetS phenotype after three months of dietary induction. We
found, as compared to LFD, an upregulation of hepatic fatty acid uptake in the HFD, HFD+C
(MetSnon-DLP) and HFD+C (MetSDLP) groups (Fig 5C).
In vivo and in silico dynamics of the development of Metabolic Syndrome
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Fig 5D shows that hepatic bile acid synthesis is predicted to be higher in the MetSDLP phe-
notype. This aspect could also be observed in the gene expression data: the expression of bile
acid synthesis genes nuclear farnesoid X receptor (FXR) and Cholesterol 7 alpha-hydroxylase
(Cyp7a1) was largely upregulated, as compared to HFD alone.
Hepatic de novo lipogenesis (Fig 5E; DNL) is predicted to be higher in the dyslipidemic pheno-
type, for which data at the 3 months’ time point was available and was used in the model fitting.
Genes related to DNL, including Fatty Acid Synthase (FASN), Acetyl-CoA carboxylase 2 (ACC2),
acyl-CoA:diacylglycerol acyltransferase 2 (DGAT2) and sterol regulatory element binding protein
1c (SREBP1c) were all largely downregulated probably as a compensatory mechanism.
In addition, the hepatic β-oxidation (Fig 5F) is predicted to be lower in the dyslipidemic
group. This could be linked to a compensatory upregulation of genes related to fatty acid β-
Fig 4. Onset and development of the Metabolic Syndrome reveals two distinct phenotypes of dyslipidemic status. The classical hallmarks of MetS are depicted by
simulations of the individual trajectories (the top 10% best were selected from n = 1,000) for the low-fat diet (LFD) are shown in light blue; high-fat diet (HFD) in dark
blue, the non-dyslipidemic Metabolic Syndrome phenotypes (MetSnon-DLP) in gray and the dyslipidemic Metabolic Syndrome phenotypes (MetSDLP) in red. The color
intensity reflects the density of the trajectories: the darker, the more probable the simulated solution. Experimental in vivo data are shown as black error bars that
represent mean ± standard deviation. The 5th column shows an overlay of the mean of the trajectories for each of the subgroups showing the development of increased
triglycerides and cholesterol levels in the plasma in the dyslipidemic MetS phenotypes between two and three months.
https://doi.org/10.1371/journal.pcbi.1006145.g004
In vivo and in silico dynamics of the development of Metabolic Syndrome
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oxidation such as Peroxisome proliferator-activated receptor α (PPARα), Peroxisomal acyl-
coenzyme A oxidase 1 (ACOX1) and Carnitine palmitoyltransferase 1a (CPT1a). Collectively,
these predictions suggest more lipid accumulation in the liver of the dyslipidemic mice.
Both Metabolic Syndrome phenotypes develop hepatic steatosis
MINGLeD with ADAPT predicted the trajectories of the liver lipid profiles and calculated the
hepatic lipid pool sizes over the entire time course of three months. Next, we measured lipid
Fig 5. Metabolic flux trajectory analysis depicts differences among phenotypes and dyslipidemia development. Trajectory analysis reveals decreased dietary
cholesterol absorption from the intestinal lumen in the non-dyslipidemic Metabolic Syndrome phenotype (a) and increased hepatic activity in the dyslipidemia
Metabolic Syndrome phenotype (b-f). The median metabolic flux trajectories (calculated from the top 10% best trajectories from n = 1,000) are depicted with a solid line
for the hepatic dietary cholesterol absorption from the intestinal lumen (a), hepatic (V)LDL-TG uptake from the plasma (b), hepatic fatty acid uptake from the plasma
(c), hepatic bile acid synthesis from cholesterol (d), hepatic de novo lipogenesis (e), and hepatic β-oxidation (f). The shaded area depicts the 10% range of trajectories
around the median. The low-fat diet cohort is depicted in light blue; the high-fat cohort in dark blue; the non-dyslipidemic Metabolic Syndrome phenotype in gray and
the dyslipidemic Metabolic Syndrome phenotype in red. The experimental hepatic de novo lipogenesis (e) data are shown as black error bars that represent
mean ± standard deviation.
https://doi.org/10.1371/journal.pcbi.1006145.g005
In vivo and in silico dynamics of the development of Metabolic Syndrome
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turnover and the lipid content in livers from individual mice after three months of dietary
induction to verify these in silico predictions at the last time point. Indeed, addition of choles-
terol did lead to an increase in lipid turnover and the hepatic lipid pool sizes as compared to
the high-fat diet without cholesterol, both in the dyslipidemic and non-dyslipidemic pheno-
type (Fig 6). Moreover, this accumulation of lipids in the liver, in particular cholesterol compo-
nents, was more profound in MetSDLP mice.
Flux trajectory analysis revealed substantial differences in hepatic fluxes between the non-
dyslipidemic and the dyslipidemic MetS phenotypes. In terms of plasma metabolite levels (see
Fig 4A–4E), MetSnon-DLP mice closely resemble the mouse population fed the HFD without
cholesterol, and intriguingly, appears not to be affected by the additional dietary cholesterol
load. MINGLeD with ADAPT predicted that this may be due to reduced dietary cholesterol
absorption (Fig 5A) in the non-dyslipidemic phenotype.
Furthermore, the predicted lipid pool sizes were in agreement with liver histology data (S1
Note-Fig 2), which showed the establishment of microvesicular steatosis upon HFD feeding.
In contrast, steatosis was exacerbated in MetSDLP mice revealed by a more severe type of
macrovesicular steatosis.
Discussion
Our goal was to design an approach to study the longitudinal and progressive dynamics of
metabolic alterations of MetS. Not only do the results show that our systems biology approach
successfully describes the multitude of the metabolic changes, our modeling approach also
describes the development of clinically relevant pathophysiological symptoms, including liver
lipid accumulation (hepatic steatosis) and reduced insulin sensitivity (pre-diabetes). This dem-
onstrates that our modeling approach can be used to study the onset and progression of MetS
as well as its co-morbidities. From the heterogeneous dataset our model identified differences
among tested individual mice. Unexpectedly, the existence of two different phenotypes in
MetS development was predicted.
Heterogeneity in phenotype development
The clinical presentation of MetS in humans is highly heterogeneous and spans over decades. Male
E3L.CETP mice fed a high-fat diet supplemented with cholesterol develop MetS within a time
scale of several months. Although all of these animals have the same genetic background, received
Fig 6. Metabolic Syndrome development is associated with hepatic steatosis in both dyslipidemic and non-dyslipidemic phenotypes. The mean trajectories of the
liver lipid profiles (calculated from the top 10% best trajectories from n = 1,000) are depicted for the hepatic triglyceride pool (a), hepatic free cholesterol pool (b) and the
hepatic cholesteryl ester pool (c). Experimental data was obtained at the end of the study and is depicted by the black error bars representing mean ± standard deviation
for each of the groups. The data from the LFD cohort is used as initial value, assuming no hepatic lipid accumulation to have occurred in this control group. Differences
between groups were determined using one-way ANOVA test. When significant differences were found, Fisher’s LSD test was used as a post hoc test to determine the
differences between two independent groups:  P<0.05;  P<0.01;  P<0.001 as compared to LFD # P<0.05; ## P<0.01; ### P<0.001 as compared to HFD $ P<0.05; $$
P<0.01; $$$ P<0.001 as compared to HFD+C (MetSnon-DLP).
https://doi.org/10.1371/journal.pcbi.1006145.g006
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the same diet and were kept and monitored in a controlled, standardized environment, this in vivo
model did show heterogeneity in phenotypic presentation. In addition, the manifestation of the
full repertoire of metabolic alterations associated with MetS makes this a useful in vivomodel,
whereas other animal models only describe one or partial metabolic aspects of MetS [53–59].
Using a traditional statistical approach, both this heterogeneity and limited datasets compris-
ing of low number of animals are problematic. Moreover, the time-dependency of the data–i.e.
individual data of consecutive points in time are interrelated and therefore not independent
samples–would further complicate analysis. Our computational modeling approach tackles
these problems by combining MINGLeD with ADAPT. Contrary to other computational mod-
els, MINGLeD integrates both glucose and lipid species at a whole-body level. Both carbohy-
drates and fats are of importance in MetS and MINGLeD allows for simultaneous description
of these key components in terms of both metabolite pool sizes (concentrations) and metabolic
fluxes. Complexity and detail in model equations was considered in close relation to what is
experimentally feasible to measure throughout long-term MetS development. Therefore,
MINGLeD’s data-driven, physiological design allows for describing both flux and concentration
data on a whole-body level. MINGLeD per se can be simulated to describe metabolic snapshots,
whereas the long-term dynamics are captured by using MINGLeD in conjunction with
ADAPT. ADAPT has been designed to work with this kind of data and makes use of the time-
dependent observations and simultaneously assesses uncertainty based on the variability in the
data. The strength of the ADAPT methodology in dealing with heterogeneity became evident
with the identification of two distinctly different phenotypes despite the limited number of ani-
mals that were studied. These two phenotypes mainly differ in terms of dyslipidemia, and flux
trajectory analysis pinpointed differences in: 1) hepatic turnover of metabolites, including lipid
fluxes and 2) the intestinal cholesterol absorption. This appears to mimic the observation in
humans showing that levels of cholesterol absorption efficiency can vary greatly among individ-
uals [60,61]. These model predictions are open for further experimental validation.
Future perspectives
The methodology of integrating in vivo and in silico information allows to combine pre-exist-
ing knowledge with experimental quantitative data and can therefore be applied to study other
multifactorial, progressive diseases where longitudinal data are available. A future application
of the model is to quantify energy intake and energy expenditure and analyze the energy bal-
ance over time for development of obesity and MetS.
Conclusion
In conclusion, we combined data from animal experiments with a computer model and com-
puter simulations to study the development of MetS. The new model predicted which changes
in the underlying metabolic processes could explain the MetS symptoms. Two different sub-
groups were identified: those with high cholesterol and high triglycerides, and those without.
The computer model found that in those who develop lipid abnormalities, both dietary choles-
terol absorption and hepatic liver fluxes were higher.
Materials and methods
Ethics statement
All animal experiments were performed in accordance with the regulations of Dutch law on
animal welfare, and the Animal Ethics Committee of the Leiden University Medical Center,
Leiden, The Netherlands. Animals were sacrificed by CO2 inhalation.
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In vivo model of Metabolic Syndrome development
The first step of our systems approach involves the gathering of in vivo data at different stages
during the development of the Metabolic Syndrome. To this end we use male APOE3-Leiden
(E3L).CETP transgenic mice as diet-induced in vivo model to study the metabolic adaptations
that occur over time.
Male E3L.CETP transgenic mice were housed under standard conditions with a 12 h light/
dark cycle (7AM-7PM), housed with 1–2 animals per conventional cage with free access to
chow diet and water, unless indicated otherwise. At the age of 11 weeks, randomized according
to body weight and plasma lipids (total cholesterol and triglycerides) and glucose, mice were
divided into three groups: mice were fed either a low-fat diet (LFD; n = 8), high-fat diet (HFD;
n = 12) or a HFD with additional cholesterol (HFD+C; 0.25%, w/w; Sigma) (HFD+C; n = 8)
for three months. The LFD has a 20% energy content derived from lard and contains 3.8 kcal/
g diet; the HFDs have a 60% energy content derived from lard and contain 5.2 kcal/g diet
(OpenSource Diets, Research Diets, Inc. New Brunswick, USA). The specific composition of
each diet is listed in S1 Note-Table 1.
During the study, body weight and food intake were measured weekly, body composition
(lean and fat mass) every other week. Blood samples were taken monthly and analyzed for glu-
cose, insulin, free fatty acids, total cholesterol, HDL-cholesterol and triglycerides. At the end of
the three months dietary induction experiment, animals were sacrificed. Livers were isolated
for measuring lipid metabolites and gene expression, and the hepatic de novo lipogenesis was
determined by using an isotope tracer. For further details on the experimental setup the reader
is referred to S1 Note. All individual data is available as S1 Data.
In silico model describing Metabolic Syndrome development
The second step of our systems approach involves the development of a dedicated in silico
model describing MetS onset and progression. To this end we have developed a novel
dynamic, computational model called Model INtegrating Glucose and Lipid Dynamics (MIN-
GLeD). This model is tailored to describe data from longitudinal studies and involves the met-
abolic system governing carbohydrate, lipid and cholesterol metabolism. It is composed of a
system of coupled, nonlinear ordinary differential equations (ODEs). The steady state of the
ODE model represents a snapshot of the metabolic state and describes the mass balance of the
metabolite pools and flux rates for carbohydrate, lipid and cholesterol species in the plasma,
liver, intestinal lumen and periphery. This in silico model aims to describe the metabolic sys-
tem in a whole-body perspective under healthy conditions as well as at different stages during
Metabolic Syndrome development.
The steady state of MINGLeD describes the average behavior of the metabolic system over
the time course of one day. Therefore no specific postprandial or fasting periods have been
included explicitly. The metabolic pathways that are important in describing the metabolic sys-
tem are presented in Fig 2. The exact block diagram of the computational model is schemati-
cally represented in S2 Note-Fig 1. The system of ODEs and fluxes equations are derived in S2
Note and listed in S2 Note-Tables 1–2.
MINGLeD describes metabolite pools originating from carbohydrate substrates (glucose,
glucose-6-phosphate, acetyl coenzyme a), lipid species (free fatty acids, triglycerides, various
lipoproteins) and cholesterol (free cholesterol, cholesteryl esters and bile acids). The metabolic
pathways that define the interactions between these metabolites include the uptake of dietary
macronutrients, glycolysis, hepatic gluconeogenesis, lipoprotein assembly and (remnant)
uptake, cholesteryl ester transfer between lipoproteins (upon action of the cholesterol ester
transfer protein; CETP), trans-intestinal cholesterol excretion (TICE), exchange between free
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cholesterol and cholesteryl esters (via ACAT and CEH) in hepatic tissue, hepatic fatty acid
uptake, peripheral lipolysis, β-oxidation, de novo lipogenesis (DNL) and cholesterol biosynthe-
sis. Bile acid synthesis, biliary bile acid and cholesterol excretion, enterohepatic reuptake, fecal
excretion of bile acids and cholesterol. Finally, metabolism of acetyl coenzyme A in hepatic
and peripheral tissues has been included.
Modeling metabolic snapshots of different phenotypes
To validate the proposed structure of the in silico model, we calibrate MINGLeD to the in vivo
data of the different metabolic snapshots. The experimentally measured metabolites are closely
related to many of the variables in the computational model, such that an identifiable model is
achieved of which the model parameters can be determined using parameter estimation. For
each of the diet cohorts, MINGLeD is fitted separately to the phenotype snapshot determined
at each month during the dietary induction period. For each snapshot, we compute the average
and standard deviation of the measured data at this time point and use this data to fit the
model to using maximum likelihood estimation. S3 Note and S3 Note-Table 1 describe how
we relate the experimentally observed data to the specific model outputs and equations using
the weighted sum of squares as error measure to be minimized. A Monte Carlo approach is
employed to account for methodological and experimental uncertainties. The optimization
procedure is repeated 500 times using a widely dispersed range of initial parameter values
(10−1–101) to accommodate multi-start optimization. The implementation details can be
found in S2 Note. Once optimized, MINGLeD predicts unobserved species and fluxes and is
used to make predictions on the underlying differences between phenotype snapshots.
Modeling phenotype transition: Modeling the onset and progressive
behavior over time
The next step in our systems approach is to couple the phenotype snapshots in time. Hereto
we make use of the computational technique entitled ‘Analysis of Dynamic Adaptations of
Parameter Trajectories’ (ADAPT) [36–38]. By employing this concept of the time-dependent
evolution of model parameters, dynamic disease trajectories are obtained from which the
onset and progression of MetS symptoms and co-morbidities can be studied. The progression
of these adaptations is predicted by identifying necessary dynamic changes in the model
parameters to describe the transition between experimental data observed at different points
in time during the dietary induction.
Since it is a priori unknown which model parameters change with time, it is not possible to
perform a dynamic simulation of the entire time span in one go. Therefore we discretize the
time span into 90 segments, each representing one day. ADAPT interpolates between the indi-
vidual snapshots in time (at which experimental data was obtained) and simulates every day in
between these time points. To facilitate this, some pre-processing steps are required. Since the
quantitative experimental data is discrete and only available at four points in time, the data is
interpolated using cubic smoothing splines to obtain continuous dynamic descriptions of the
experimentally observed metabolite pools and fluxes. To account for experimental and biologi-
cal uncertainties, a collection of 1,000 splines is calculated using a Monte Carlo approach: dif-
ferent random samples of the experimental data are generated assuming Gaussian
distributions with means and standard deviations of the data. Subsequently, for each generated
sample, a cubic smoothing spline is calculated. This bootstrapping approach yields samples of
data replicates which will subsequently be utilized in parameter estimation [62]. By combining
bootstrapping of data, sampling of parameters and a robust optimization of model simulations,
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ADAPT provides feedback about uncertainty in model predictions accounting for uncertainty
in both experimental measurements and fitting procedures.
The system is first simulated for the phenotype prior to the dietary induction by optimiza-
tion to the t = 0 data. For each step in time, the system is simulated using the final values of the
model states of the previous time step as initial conditions. Since we consider the parameters
to be time-varying, the model parameters are re-optimized for each time step by minimizing
the difference between the (sampled and interpolated) experimental data and the correspond-
ing model outputs. The estimated parameter set from the previous time point is used as initial
set for the optimization procedure. It is assumed that the induced adaptations are minimal and
proceed progressively in time. Therefore, highly fluctuating parameter trajectories are consid-
ered to be non-physiological. To prevent the occurrence of such behavior, the parameter esti-
mation protocol is extended to prevent unnecessary change of parameters and to identify
minimal parameter adaptations that are required to describe phenotype transition. The cost
function is extended with a regularization term (see Eq 2 in S3 Note), given by the sum of
squared derivatives of the normalized parameter values. Hence, changing a parameter is costly,
and will therefore be avoided if this is not required to describe the experimental data. The con-
stant λ that determines the strength of this regularization term, should be chosen carefully
such that the data fitting is biased as little as possible. If too large a value for λ is chosen, the
regularization term becomes dominant and the model will not describe the experimental data
accurately anymore. Since a small λ is already sufficient to minimize parameter changes and
fluctuations, whilst still describing the experimental data accurately, λ was set to 0.1 in this
study.
All simulation code and in silico data files are available on GitHub (via https://github.com/
yvonnerozendaal/MINGLeD).
ADAPT yields a collection of parameter sets that describe the dynamics of the onset and
development of MetS over time. The obtained trajectories for the model parameters, but also
for the fluxes and pool sizes provide insight in the affected underlying biological system. This
provides information about the adaptations that have taken place during the dietary induction,
and these model-based predictions are compared to the gene expression data that is measured
at the end of the dietary induction study.
Supporting information
S1 Fig. Predicted metabolite pools and flux trajectories. Panels a-b display the dynamics in
metabolite pools over time and panels e-t display the corresponding flux trajectories. We
selected the n = 100 best trajectories (top 10% based on WSSE). The 10% range around the
median trajectory is depicted by the shaded area and the median trajectory for each model
component is depicted by the solid line for the low-fat diet group (light blue), high-fat diet
group (dark blue), non-dyslipidemic Metabolic Syndrome phenotype (gray) and the dyslipi-
demic Metabolic Syndrome phenotype (red) respectively. Experimental data is represented by
the black error bars (mean ± standard deviation).
(PDF)
S1 Note. Experimental setup.
(PDF)
S2 Note. Detailed model description of MINGLeD.
(PDF)
S3 Note. Data used for model calibration.
(PDF)
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